<DOC>
	<DOCNO>NCT00742599</DOCNO>
	<brief_summary>Patients require gastric endoscopy receive intragastric single dose NPO-11 20 mL . The superiority NPO-11 placebo premedication endoscopy verify randomize , double-blind , parallel-assignment design base percentage patient gastric peristalsis 2 minute post-dose end endoscopy ( primary outcome measure ) . The safety NPO-11 evaluate base adverse event adverse drug reaction ( ADRs ) observe administration seven day administration comparison placebo group .</brief_summary>
	<brief_title>Phase III Controlled Clinical Study NPO-11 Patients Undergoing Gastric Endoscopy</brief_title>
	<detailed_description />
	<criteria>Inpatients outpatient either sex visit medical institution treatment followup confirm suspected upper gastrointestinal disease ( symptom ) meet criterion ( 1 ) ( 2 ) enrol study . Patients provide write informed consent voluntary participation study . 1 . Patients need gastric endoscopy ( except endoscopy scope &lt; 9 mm diameter , emergency endoscopy endoscopy comprehensive medical examination ) 2 . Patients older 20 year time consent Patients meet follow criterion exclude study . The criterion ( 2 ) ( 5 ) confirm endoscopy . Patients meet criterion withdraw study time confirmation . 1 . Patients history surgery upper gastrointestinal tract 2 . Patients severe gastric stenosis deformation make observation gastric peristalsis difficult 3 . Patients upper gastrointestinal bleeding require hemostasis 4 . Patients reflux esophagitis ( Los Angeles classification : B , C D ) 5 . Patients gastric duodenal ulcer active stage 6 . Patients cancer treatment ( chemotherapy radiotherapy ) 7 . Patients impaired cardiac function ( NYHA functional classification : III IV ) 8 . Patients history shock hypersensitivity lmenthol peppermint oil ( mint oil ) 9 . Patients history shock hypersensitivity lidocaine hydrochloride 10 . Pregnant lactate woman , woman childbearing potential , woman plan become pregnant study 11 . Patients expose NPO11 12 . Patients receive investigational drug within four month consent participate clinical study 13 . Patients otherwise ineligible participation study investigator 's subinvestigator 's opinion</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Stomach Diseases</keyword>
</DOC>